Spotlight on the January 24 Issue

Objective: To determine the relationship between β-amyloid (Aβ) load as measured by [11C]–Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults. Methods: We studied 408 cognitively normal older adults who participated in the population-based Mayo Clinic Study of Aging (MCSA) from January 2009 through March 2011. The participants underwent PiB PET and neuropsychometric testing within 6 months. The association between PiB retention and cognitive function was measured by partial correlation and an interaction with APOE status was tested using linear regression after adjusting for age, sex, and education. Results: Higher PiB retention was associated with cognitive performance (Spearman partial r = −0.18; p < 0.01), specifically the memory, language, attention/executive, and visual-spatial processing domains in the whole group of participants. The association between PiB retention and cognition was modified by the APOE status on linear regression analysis even after controlling for the differences in the distribution of PiB values among APOE ϵ4 carriers and noncarriers (p = 0.02). Cognitive performance was associated with the Aβ deposition in the frontal, temporal, and parietal lobe association cortices in APOE ϵ4 carriers on SPM analysis (p < 0.001). Conclusion: There is a modest association between PiB retention and cognitive function in cognitively normal older adults and this relationship between Aβ load and cognitive function is modified by APOE status. Whereas Aβ load is associated with greater cognitive impairment in APOE ϵ4 carriers, the cognitive function in APOE ϵ4 noncarriers is influenced less by the Aβ load, suggesting that APOE isoforms modulate the harmful effects of Aβ on cognitive function. Neurology® 2012;78:232–240

[1]  Eric M Reiman,et al.  The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[2]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[3]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[4]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[5]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[6]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[7]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[8]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[9]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[10]  C. Rowe,et al.  Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.

[11]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[12]  E G Tangalos,et al.  Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.

[13]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[14]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[15]  Michael Weiner,et al.  Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition , 2011, Alzheimer's & Dementia.

[16]  J. Ávila,et al.  The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. , 1996, Molecular and chemical neuropathology.

[17]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[18]  Clifford R. Jack,et al.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage , 2008, NeuroImage.

[19]  E. Reiman,et al.  Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. , 2010, Journal of Alzheimer's disease : JAD.

[20]  K. Welsh-Bohmer,et al.  APOE-ε4 count predicts age when prevalence of AD increases, then declines , 1999, Neurology.

[21]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[22]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[23]  Sachin Dixit,et al.  APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 , 2010, The Journal of Neuroscience.

[24]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[25]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[27]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[28]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[29]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[30]  D. Berlau,et al.  APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.

[31]  Ge Li,et al.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.

[32]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[33]  Michael Schemper,et al.  Non-parametric partial association revisited , 1991 .

[34]  R. Petersen,et al.  The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. , 2009, Neuropsychology.

[35]  K. Ashe,et al.  Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function , 2008, Neuroscience.

[36]  M. Mintun,et al.  Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. , 2008, Archives of neurology.

[37]  Clifford R. Jack,et al.  Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition , 2011, Alzheimer's & Dementia.

[38]  R. Verwer,et al.  ApoE ϵ4 Genotype Is Accompanied by Lower Metabolic Activity in Nucleus Basalis of Meynert Neurons in Alzheimer Patients and Controls as Indicated by the Size of the Golgi Apparatus , 2004, Journal of neuropathology and experimental neurology.

[39]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[40]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[41]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[42]  B W Wyse,et al.  APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. , 1999, Neurology.

[43]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.